EXC
72
3
NWSA
76
3
MAR
56
3
CME
52
2
INTU
68
6
JPM
66
4
MS
68
2
ORCL
60
2
DVA
61
2
AMGN
23
3
ETR
65
-3
DUK
60
5
F
43
-4
M
33
2
MDLZ
65
4
EBAY
44
4
NWL
35
3
PH
70
3
MCO
67
3
ED
43
3
EXC
72
3
NWSA
76
3
MAR
56
3
CME
52
2
INTU
68
6
JPM
66
4
MS
68
2
ORCL
60
2
DVA
61
2
AMGN
23
3
ETR
65
-3
DUK
60
5
F
43
-4
M
33
2
MDLZ
65
4
EBAY
44
4
NWL
35
3
PH
70
3
MCO
67
3
ED
43
3
Financhill
Back

Aurinia Pharmaceuticals 10K Form

Buy
52

AUPH
Aurinia Pharmaceuticals

Last Price:
$8.17
Seasonality Move:
-14.7%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2023-11-02 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2023-08-03 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2023-05-04 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2022-11-03 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2022-08-04 10Q AUPH/Aurinia Pharmaceuticals Quarterly

Receive AUPH News And Ratings

See the #1 stock for the next 7 days that we like better than AUPH

AUPH Financial Statistics

Sales & Book Value

Annual Sales: $235.1M
Cash Flow: $30.1M
Price / Cash Flow: 26.86
Annual Sales: $2.68
Price / Book: 2.94

Profitability

EPS (TTM): 0.05000
Net Income (TTM): $5.8M
Gross Margin: $206.9M
Return on Equity: 1.54%
Return on Assets: 1.07%

Aurinia Pharmaceuticals Earnings Forecast

Key Aurinia Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 27 years for AUPH is 87.99%.
  • The Selling, General & Administrative Expenses for AUPH have been equal to 73.16% of Gross Profit Margin.
  • The Research & Development expenses have been 8.84% of Revenue.
  • The Interest Expense is 84.06% of Operating Income.
  • The Net Earning history of AUPH is 2.45% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 15 years.

Aurinia Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUPH
CUSIP: 05156V
Website: auriniapharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.57
Quick Ratio: 4.04

Price-to-Earnings

Trailing P/E Ratio: 203
Forward P/E Ratio: 11.5

AUPH Technical Analysis vs Fundamental Analysis

Buy
52
Aurinia Pharmaceuticals (AUPH) is a Buy

Is Aurinia Pharmaceuticals a Buy or a Sell?